Organization (Industry)
CytomX Therapeutics, Inc.
ClinicalTrials.gov lists CytomX Therapeutics, Inc. as lead sponsor of 10 trials. It has 29 active development programs and 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through October, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.6 trial starts a year over the five years to October, under the 5 a year the method needs.
This page covers CytomX Therapeutics, Inc.: 10 lead-sponsored trials and 3 legal-entity registrations.
Disease areas (15)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Breast Neoplasms | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Head and Neck Neoplasms | 2 |
| Lung Neoplasms | 2 |
| Lymphoma | 2 |
Showing 5 of 15 disease areas.
Trials by start year as sponsor or collaborator (7)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2024 | 2 |
| 2022 | 1 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 2 |
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (29)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials | Ownership basis |
|---|---|---|---|---|
| CX-2009 | Breast Neoplasms | Phase 2 | 2 | Experimental arm |
| IPILIMUMAB | Melanoma | Phase 2 | 1 | Crowded, not lead |
| IPILIMUMAB | Recurrence | Phase 2 | 1 | Crowded, not lead |
| CX-2009 | Triple Negative Breast Neoplasms | Phase 2 | 1 | Experimental arm |
| CX-072 | Breast Neoplasms | Phase 2 | 1 | Experimental arm |
Showing 5 of 29 active programs.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials | Ownership basis |
|---|---|---|
| IPILIMUMAB | 2 | Crowded, not lead |
| BEVACIZUMAB | 2 | Generic, not holder |
| Vemurafenib | 1 | Crowded, not lead |
| PEMBROLIZUMAB | 1 | Crowded, not lead |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 0% hit target (n=7) | 33% on time (n=6) |
Journals published in (2)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal for immunotherapy of cancer | 2 |
| Clinical cancer research : an official journal of the American Association for Cancer Research | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 87 | 32 | 2025-12-23 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts; non-USD filers converted to USD at the annual average rate.
| Fiscal year | Revenue | Net income | R&D |
|---|---|---|---|
| 2025 | $76.2M | -$17.4M | $68.7M |
| 2024 | $138M | $31.9M | $83.4M |
| 2023 | $101M | -$569K | $77.7M |
| 2022 | $53.2M | -$99.3M | $112M |
| 2021 | $37.3M | -$116M | $114M |
| 2020 | $100M | -$32.9M | $113M |
| 2019 | $57.5M | -$102M | $132M |
| 2018 | $59.5M | -$84.6M | $104M |
| 2017 | $71.6M | -$43.1M | $92.3M |
| 2016 | $12.8M | -$58.9M | $54.8M |
Showing 10 of 11 fiscal years.
Cash runway about 23 months at the end of FY2025. Estimate, derived not reported: $137M of cash and investments over $72.6M a year of net cash used in operations, averaged over the 3 reported fiscal years to FY2025.
Financing and grant events (23)
Shown in this order: most recent first; amounts in US dollars.
| Date | Round type | Amount | Source |
|---|---|---|---|
| 2026-05-29 | Royalty / licensing | $37 | SEC extracted |
| 2026-03-19 | Public offering | $234M | SEC extracted |
| 2026-03-18 | Follow-on offering | $287M Registered offering ceiling | EDGAR offerings |
| 2026-03-16 | Follow-on offering | not disclosed | EDGAR offerings |
| 2026-03-16 | Other financing | not disclosed | EDGAR offerings |
Showing 5 of 23 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Latest dated events (120)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-12 | Planned start | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-29 | Royalty / licensing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-03-19 | Public offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-03-18 | Follow-on offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-03-16 | Follow-on offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 120 events.
Biomarker capability evidence (7)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD274 | Trial sponsor | Named in trial inclusion criteria |
| ERBB2 | Trial sponsor | Named in trial inclusion criteria |
| PDCD1 | Trial sponsor | Named in trial exclusion criteria |
| CD274 | Trial sponsor | Mentioned in trial text |
| ERBB2 | Trial sponsor | Mentioned in trial text |
Showing 5 of 7 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.